Survival in Small-Cell Lung Cancer Improved With Cytotoxic Add-On to Immunotherapy

(MedPage Today) -- CHICAGO -- Patients with extensive-stage small-cell lung cancer (SCLC) lived significantly longer with the addition of cytotoxic agent lurbinectedin (Zepzelca) to maintenance immunotherapy, a large randomized trial showed...